Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
about
The CCR5- 32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single sourceHost Genetic Factors and Antiviral Immune Responses to Hepatitis C VirusRole of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infectionCCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug usersInterference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injuryGenes and hepatitis C: susceptibility, fibrosis progression and response to treatment.Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation.CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients.Chemokines in the immunopathogenesis of hepatitis C infectionThe association of toll-like receptor 4 polymorphism with hepatitis C virus infection in Saudi Arabian patients.CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.Clinical significance of the CCR5delta32 allele in hepatitis CCCR5 receptor: biologic and genetic implications in age-related diseases.Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearanceImmunoprivileged status of the liver is controlled by Toll-like receptor 3 signalingOctreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells.Dysfunction of Immune Systems and Host Genetic Factors in Hepatitis C Virus Infection with Persistent Normal ALT.The history of the "natural history" of hepatitis C (1968-2009).Fibrosis progression in chronic hepatitis C virus infection.Host genetic determinants in hepatitis C virus infection.Predictive factors associated with hepatitis C antiviral therapy response.Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection -- a prospective cross-sectional studyThe chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility.The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis.Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.CCR1 and CCR5 promote hepatic fibrosis in miceA Study of CC-Chemokine Receptor 5 (CCR5) Polymorphism on the Outcome of HCV Therapy in Egyptian Patients.CCL5: a double-edged sword in host defense against the hepatitis C virus.Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections.Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.Stem cell-based therapies for HIV/AIDS.Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection.Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.Association of TIMP-1 and TIMP-2 gene polymorphisms with progression of liver fibrosis in patients with type C chronic liver disease.Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.
P2860
Q27477986-D7EBFAAE-B864-4821-B45D-D253EC2210BEQ27487445-53B0F1DC-90F7-46E7-98DD-7CAE8833400CQ27490393-7D1FE66D-7C76-4ADE-89AE-D4FCA4D9D8DBQ28534869-8E80AE5B-8DBF-4E62-93C2-502C839FCE71Q28730116-AD74B623-72D3-4064-852D-D0C594D16917Q33350754-BF432B11-48BA-4379-80CF-F856D46E5A29Q33747313-B2B63EF6-762E-469D-AB54-A26669F53070Q33867870-1A4126A6-D25D-4666-ADB0-827EBD1AA4ADQ33912466-EA18226A-98A7-4DD3-A6C6-815D1EE3ED05Q34056271-278E8361-B45C-444D-93CF-EA4FD6F75C66Q34081261-26099902-40A9-4A71-AD49-F9CD25D7BDD6Q34098888-0DD43FE1-259D-41E1-BA95-ADE1D9D35031Q34142349-6B13C767-6B5B-458F-B5D6-12496F02F489Q34622935-53338022-F5D4-4671-A577-70A84539ABCEQ34914406-8AE5417E-3693-4A4A-8EEE-D43954392EC6Q35009476-0ADA20E4-AB18-473B-A632-3B7C58ADE557Q35046099-8845A73B-0F2B-48E2-93FE-2991B81EBDBBQ35094287-8018EFDD-CC2E-43B4-9C69-88A9FB6EF1B2Q35216592-F3B6436A-744A-4BAB-B3B6-177B18E96DA9Q35666213-4E1C4311-D542-4CB6-B3D3-BF325FA3E75EQ35753723-50463940-4EB3-4EE7-B8AA-01432A1E837BQ35790397-96AB3BF5-A83C-4D3C-8706-1A963A238FFAQ36503328-82668706-9617-43A0-86D6-5590875725ABQ36937324-9CD60E1A-5D26-4AFC-B73A-CC06F0248585Q36944050-9C857048-259F-402C-AF70-CAD52D216B78Q37196855-554B8102-E541-49AA-8B60-790B6EB1240DQ37225844-5DBD5BFF-C548-4D53-ADB9-7AB44C6B4FBAQ37241370-8C05752D-55AD-4ECC-95B9-B17044C1DF86Q37424353-EA00597F-93D6-4FD5-8613-3EC39DFADAC9Q37952808-489B5DAD-DFAC-402C-87DF-82B0D3188150Q38088855-349B1AAD-C82B-49E3-96BA-126C9DF4B5A9Q38157936-5CC01A75-78FD-4685-A841-1038204A2A71Q38827119-60491AD8-E5AA-4B2F-94BD-0CE0A46B696AQ39639458-E97A1D77-FF16-48B9-8849-15E283289E43Q42984759-176957F4-184C-4534-BBA4-4DCCEC00E31EQ42988911-E0887632-9C47-44FC-BE4F-0EF21C91BD2CQ43023517-32980E6F-EAC9-405A-BB0A-368E6C01BFFCQ43742587-4B984778-B522-4E7E-97FF-DBBE49560426Q44246682-89862B9E-6D6D-41E7-B898-59ABC9C66EBDQ44394482-066630A0-09B9-4854-A592-01A326400CD8
P2860
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Associations of chemokine syst ...... ponses of chronic hepatitis C.
@en
Associations of chemokine syst ...... ponses of chronic hepatitis C.
@nl
type
label
Associations of chemokine syst ...... ponses of chronic hepatitis C.
@en
Associations of chemokine syst ...... ponses of chronic hepatitis C.
@nl
prefLabel
Associations of chemokine syst ...... ponses of chronic hepatitis C.
@en
Associations of chemokine syst ...... ponses of chronic hepatitis C.
@nl
P2093
P50
P356
P1433
P1476
Associations of chemokine syst ...... ponses of chronic hepatitis C.
@en
P2093
Alejandro Soza
Carlos M Gonzalez
Deloris E Koziol
Harvey J Alter
Jay H Hoofnagle
Kittichai Promrat
Marc Ghany
Matthew Lessie
Maya Merrell
T Jake Liang
P304
P356
10.1053/GAST.2003.50061
P407
P577
2003-02-01T00:00:00Z